Published in final edited form as:

Bioorg Med Chem Lett. 2016 July 1; 26(13): 3167–3171. doi:10.1016/j.bmcl.2016.04.080.

Sequential one-pot synthesis of bis(indolyl)glyoxylamides: Evaluation of antibacterial and anticancer activities

Mukund P. Tantak^a, Vishakha Gupta^a, Kumar Nikhil^b, V. Arun^a, Rajnish Prakash Singh^c, Prabhat Nath Jha^c, Kavita Shah^{b,*}, and Dalip Kumar^{a,*}

^aDepartment of Chemistry, Birla Institute of Technology and Science, Pilani- 333 031, India

^bDepartment of Chemistry, Purdue University Center for Cancer Research, Purdue University, 560 Oval Drive, West Lafayette, IN 47907 (USA)

^cDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani 333031, Rajasthan, India

Abstract

A series of bis(indolyl)glyoxylamides **10a–n** has been designed and synthesized. *In situ* generated indole-3-glyoxalylchloride from the reaction of readily available indole **9** with oxalyl chloride was treated with tryptamine to produce bis(indolyl)glyoxylamides **10a–n** in 82–93% yields. All the synthesized bis(indolyl)glyoxylamides were well characterized and tested for their antibacterial activity against Gram-positive and Gram-negative bacterial strains. Compounds **10d**, **10g** and **10i** were found to display potent antibacterial activity against Gram-negative strain. Further, the cytotoxicity of bis(indolyl)glyoxylamides **10a–n** were evaluated against a panel of human cancer cell lines. Of the screened analogues, compound **10f** (IC₅₀ = 22.34 μM; HeLa, 24.05 μM; PC-3, 21.13 μM; MDA-MB-231 and 29.94 μM; BxPC-3) was identified as the most potent analogue of the series. Exposure of PC-3 cells to either **10a** or **10f** resulted in increased levels of cleaved PARP1, indicating that bis(indolyl)glyoxylamides induce apoptosis in PC-3 cells. Most importantly, compounds **10d**, **10g** and **10i** were completely ineffective in mammalian cells, suggesting that they target bacterial-specific targets and thus will not display any toxicity in host cells.

Graphical Abstract

*Corresponding authors. Tel.: +91-1596-515238 (D.K.); +1 765 496 9470 (K.S.) dalipk@pilani.bits-pilani.ac.in (D. Kumar), shah23@purdue.edu (K. Shah).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary data

Supplementary data (experimental procedures and characterization data for compounds **10a–n** associated with this article can be found, in the online version, at <http://dx.doi.org/>

Keywords

Bisindoles; Glyoxylamides; Antibacterial; Cancer; Cytotoxicity; Apoptosis

Indole is a core substructure in a wide range of biologically active natural products isolated from marine organisms.¹ Particularly, diverse indole alkaloids represent an emerging class of natural products due to their biological potential as antimicrobial, anti-HIV, antipsychotic, antidepressant, antioxidant, anti-inflammatory and antitumour.² Among the indole alkaloids, bisindoles are a class of compounds which have received increasing attention due their diverse and profound biological activities including antimicrobial, anticancer, anti-HIV antileishmanial and anti-inflammatory.³ Due to unique structural features and associated activities, bisindole alkaloids continue to serve as potential targets for synthetic and biomedical purposes. Literature review on bisindole scaffold reveals its wide presence in many antibacterial and anticancer lead molecules.⁴ Bartik and co-workers isolated three new bisindole alkaloids namely topsentin (**1a**), bromotopsentin (**1b**) and deoxytopsentin (**1c**) from the Mediterranean sponge *Topsentia genitrix*, near Banyuls in France.⁵ Topsentin (**1a**) exhibited anticancer activity ($IC_{50} \sim 4\text{--}40 \mu\text{M}$) towards cultured human and murine tumor cells whereas bromotopsentin (**1b**, $IC_{50} = 12 \mu\text{g/mL}$) and deoxytopsentin (**1c**, $IC_{50} = 6.3 \mu\text{g/mL}$) were found to be cytotoxic against human broncopulmonary (NSCLC-N6) cancer cells. Deoxytopsentin **1c** also showed potent antibacterial activity against various bacteria ($MIC = 3.12\text{--}12.5 \mu\text{g/mL}$).⁴ Among the four bisindole alkaloids isolated by Kobayashi and co-workers from Okinawan tunicate *Rhopalaea* sp.,⁶ Rhopaladin B (**2a**) exhibited inhibitory activity against cyclin dependent kinase 4 ($IC_{50} = 12.5 \mu\text{g/mL}$) and c-erbB-2 kinase ($IC_{50} = 7.4 \mu\text{g/mL}$). Rhopaladin C (**2b**) with C₆-bromo moiety was found to display activity against *Sarcina lutea* and *Corynebacterium xerosis* bacterial strains ($MIC = \sim 16 \mu\text{g/mL}$).⁷ Hamacanthin A (**3**) containing a six-membered pyrazinone spacer unit was isolated from a deep-water marine sponge *Hamacantha* sp. and found to possess significant antimicrobial activity against *C. Albicans*, *C. Neoformans*, and *Bacillus subtilis*.⁸ With a similar pyrazinone linker, in 1995 Capon and co-workers reported the isolation of dragmacidin D (**4**) from marine sponge *Spongosorites* sp and evaluated their biological activities. Compound **4** was more active towards bacteria including *Escherichia coli* ($MIC = 15.6 \mu\text{g/mL}$); *Bacillus subtilis* ($MIC = 3.1 \mu\text{g/mL}$); *Pseudomonas aeruginosa* ($MIC = 62.5 \mu\text{g/mL}$). Also, it was more cytotoxic against P388 murine ($IC_{50} = 1.4 \mu\text{g/mL}$) and A-549 ($IC_{50} = 4.5 \mu\text{g/mL}$) human lung cancer cells (Fig. 1).⁹

In recent past numerous bisindoles containing linear as well as cyclic linkers have been identified as antibacterial and anticancer agents (Fig. 2).¹⁰ Kumar et al. prepared 3,2'-linked bisindoles **5** which were found to be active against Gram-positive and Gram-negative bacteria.¹¹ In 2011, Singh group investigated a series of *N*-1, C-3 and C-5 trisubstituted bisindoles bearing glyoxylamide functionality **6** as potent antimicrobial agents.¹² Recently, we have discovered 2-(3'-indolyl)-*N*-arylthiazole-4-carboxamides and carbazolyglyoxamides **7** as anticancer and antibacterial agents.¹³⁻¹⁴ Inspired from our previous results and profound antibacterial and anticancer properties of bisindoles, in this report we designed novel bis(indolyl)glyoxylamides by retaining the key structural features of bisindoles and glyoxylamides as depicted in Figure 2.

Bis(indolyl)glyoxylamides **10a–n** were prepared by following the synthetic route illustrated in scheme 1. *N*-alkyl indoles **9a–d** were prepared by following the reported reaction condition in 80–92%.¹⁴ Initially, the reaction of indole **9** with oxalyl chloride generated indole-3-glyoxylchloride. Further reaction of indole-3-glyoxylchloride with tryptamine afforded bis(indolyl)-glyoxylamide **10** in 82–93% yields.

Preparation of compound **10** was further simplified by performing the reaction in a sequential one-pot fashion. From the reaction of indole **9** and oxalyl chloride *in situ* generated indole-3-glyoxylchloride was subsequently treated with tryptamine and furnished bis(indolyl)glyoxylamides **10a–n** in 82–93% yields.¹⁵

Synthesized bis(indolyl)glyoxylamides **10a–n** were initially screened for *in vitro* antibacterial activity against two Gram-positive bacteria (*Bacillus subtilis* & *Staphylococcus aureus*) and three Gram-negative bacteria (*Escherichia coli*, *Pseudomonas putida*, & *Klebsiella pneumonia*). Chloramphenicol was used as a positive control. The activity results in form of zone of inhibition (ZOI) and minimum inhibitory concentration (MIC)) are given in Table 1.

Unsubstituted bis(indolyl)glyoxylamide **10a** was moderately active against the tested bacterial strains. Introduction of methoxy or bromo group (compounds **10b** and **10c**) at C-5 position of indole ring did not improve the activity. Interestingly, compound **10d** with fluorine substituent exhibited strong antibacterial activity against all the tested bacterial strains with MIC values ranging from 12.5 to 25 µg/mL (ZOI = 17–20 mm). Improved antibacterial activity of **10d** is likely due to the presence of fluorine, which is known to enhance lipophilicity and stability of the molecule.¹⁶ By changing the position (C-5 to C-6) of methoxy and fluoro groups in the indole ring resulted to inactive analogues **10e** and **10f**. Methylation of indole *N*-H led to compound **10g** with four-fold (**10a** vs **10g**) enhanced activity against Gram-negative bacteria *E. coli* (MIC = 12.5 µg/mL). Replacement of *N*-methyl with *N*-ethyl led to dramatic loss in activity (compound **10h**). However, *N*-alkylation with a bulkier 4-chlorobenzyl group resulted in compound **10i** with significantly improved (four-fold) activity against Gram-negative bacteria *E. coli* and *P. putida* (MIC = 12.5 µg/mL; ZOI = 18 mm). Substituents such as bromo (**10j**), methoxy (**10k** and **10m**) and fluoro (**10l**) in the indole ring or replacement of *N*-4-chlorobenzyl with *N*-4-fluorobenzyl (**10n**) resulted in substantial loss of activity (**10i** vs **10j–n**). From the structure-activity relationship study of bis(indolyl)glyoxylamides it was established that combination of indole with 5-fluoroindole or *N*-alkyl (methyl or 4-chlorobenzyl) was favorable for the antibacterial activity.

Figure 3 represents the time dependent killing kinetics of antimicrobial active for compounds **10d**, **10g** and **10i** against the *E. coli* (Figure 3A), *P. putida* (Figure 3B), *B. subtilis* (Figure 3C) and *S. aureus* (Figure 3D) bacterial strains. In the case of Gram-negative bacteria, these compounds showed 80–95% bactericidal activity within initial 2 h. This clearly indicates that these compounds showed fastest bactericidal action by quickly inhibiting the bacterial proliferation and thereafter achieving maximum bacterial reduction in the subsequent hour. It is evident from Figure 3 that **10d** was more effective with the higher killing activity when compared to derivatives **10g** and **10i** against Gram-negative bacteria. Similarly, for the Gram-positive bacteria, compounds **10d**, **10g**, and **10i** showed

good antibacterial activity by achieving bactericidal effect against *B. subtilis* (>80%) and *S. aureus* (>65%), within initial 2 h of incubation.

After assessing the antibacterial activity of bis(indolyl) glyoxylamides **10a–n**, we next evaluated their cytotoxicity against human embryonic kidney 293 (HEK 293T), human prostate (PC-3 and castration-resistant prostate C4-2), cervical (HeLa), breast (MDA-MB-231) and pancreatic BxPC-3 cancer cell lines using MTT assay. The goal was to not only identify potent antibacterial compounds but also ensure that they display minimal cytotoxicity in mammalian cells. Doxorubicin was used as a reference drug and the activity results are summarized in Table 2. Unsubstituted bis(indolyl)glyoxalylamide **10a** was found to be moderately active with IC₅₀ value ranging 38–97 μ M against the tested cell lines. Substitution on indole ring was unfavourable for the activity except compound **10f** with 6-fluoroindole moiety was found to be more cytotoxic towards the tested cancer cells.

Compound **10f** exhibited moderate cytotoxicity against HeLa, PC-3, MDA-MB-231 and BxPC-3 cells with IC₅₀ values of 22.34, 24.05, 21.13 and 29.94 μ M, respectively. Further, substitution on indole *N*-H resulted in inactive compounds **10g–n**. Most importantly, compounds **10d**, **10g** and **10i**, which displayed potent antibacterial activities, showed no toxicity in any of the human cell lines even at 100 μ M concentration, suggesting that these compounds likely target bacterial-specific pathways. Notably, the compound **10d** was found to be stable at pH 4.5 and 7.4 up to 48 h, however, it is sparingly soluble in water (0.3 μ g/mL).

To determine the mode of cellular death caused by bis(indolyl)glyoxylamides, compounds **10a** (IC₅₀ = 38.45 μ M,) and **10f** (IC₅₀ = 24.05 μ M) with moderate cytotoxicity against PC-3 cells, were treated for 48 h, and cleaved PARP1 levels were analyzed using immunoblot analysis. As shown in Figure 4, exposure of PC-3 cells to either **10a** or **10f** resulted in increased levels of cleaved PARP1, thereby, confirming that both the compounds led to apoptotic induced cell death in PC-3 cells.

In summary, we have synthesized and investigated antibacterial and anticancer activities of fourteen novel bis(indolyl)glyoxylamides **10a–n**. Compounds **10d**, **10g** and **10i** were identified with significant activities and could be promising candidates as antibacterial agents. Cell death assay study revealed that **10d** was more effective by exerting higher killing activity against the Gram-negative bacterial pathogens. Furthermore, in anticancer activity evaluation of bis(indolyl)glyoxylamides led to compounds **10a** and **10f** with moderate activity against the tested cancer lines. Exposure of PC-3 cells to either **10a** or **10f** resulted in the enhancement of cleaved PARP1 levels, indicating that bis(indolyl)glyoxylamides induced apoptosis in PC-3 cells.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the financial support received from DBT, New Delhi (D.K.) and NIH R03 CA166912 (K.S.).

References and notes

- (a) Pauletti PM, Cintra LS, Braguine CG, Cunha WR, Januário AH. *Mar. Drugs*. 2010; 8:1526. [PubMed: 20559487] (b) Kaushik NK, Kaushik N, Attri P, Kumar N, Kim CH, Verma AK, Choi EH. *Molecules*. 2013; 18:6620. [PubMed: 23743888]
- Kochanowska-Karamyan AJ, Hamann MT. *Chem. Rev.* 2010; 110:4489. [PubMed: 20380420]
- (a) Yang C-G, Huang H, Jiang B. *Curr. Org. Chem.* 2004; 8:1691. (b) Gupta L, Talwar A, Palne S, Gupta S, Chauhan P. *Bioorg. Med. Chem. Lett.* 2007; 17:4075. [PubMed: 17548194]
- Gupta L, Talwar A, Chauhan PM. *Curr. Med. Chem.* 2007; 14:1789. [PubMed: 17627517]
- Veale CGL, Zoraghi R, Young RM, Morrison JP, Pretheeban M, Lobb KA, Reiner NE, Andersen RJ, Davies-Coleman MT. *J. Nat. Prod.* 2015; 78:355. [PubMed: 25372480]
- Janosik T, Johnson A-L, Bergman J. *Tetrahedron*. 2002; 58:2813.
- Sato H, Tsuda M, Watanabe K, Kobayashi J. *Tetrahedron*. 1998; 54:8687.
- Gunasekera SP, McCarthy PJ, Kelly-Borges M. *J. Nat. Prod.* 1994; 57:1437. [PubMed: 7807127]
- Garg NK, Sarpong R, Stoltz BM. *J. Am. Chem. Soc.* 2002; 124:13179. [PubMed: 12405846]
- Ma Y, Yakushijin K, Miyake F, Horne D. *Tetrahedron Lett.* 2009; 50:4343.
- Mielczarek M, Devakaram RV, Ma C, Yang X, Kandemir H, Purwono B, Black DS, Griffith R, Lewis PJ, Kumar N. *Org. Biomol. Chem.* 2014; 12:2882. [PubMed: 24668488]
- Singh P, Verma P, Yadav B, Komath SS. *Bioorg. Med. Chem. Lett.* 2011; 21:3367. [PubMed: 21524574]
- Tantak MP, Wang J, Singh RP, Kumar A, Shah K, Kumar D. *Bioorg. Med. Chem. Lett.* 2015; 25:4225. [PubMed: 26298501]
- Venkataramana Reddy P, Tantak MP, Valdez R, Singh RP, Singh OM, Sadana R, Kumar D. *RSC Adv.* 2016; 6:9379.
- General procedure for the preparation of bis(indolyl) glyoxalamides 10a–n.* To a cooled (0 °C) solution of indole **9** (1.7 mmol) in THF (5 mL) was added oxalyl chloride (0.227 g, 1.7 mmol) and the resulting mixture was stirred at same temperature for 1 h. Subsequently, tryptamine (0.28 g, 1.7 mmol) and triethylamine (1 mL, 5.4 mmol) were added at 25 °C and the contents were allowed to stir for 4 h. Upon completion of the reaction as indicated by TLC, solvent was removed in vacuo. The residue so obtained was purified by column chromatography using ethyl acetate:hexane as an eluent to obtain pure bis(indolyl)-glyoxalamides **10a–n** in 82–93% yields. *Spectral data for selected compounds:* *N*-(2-(1*H*-Indol-3-yl)ethyl)-2-(1*H*-indol-3-yl)-2-oxoacetamide (**10a**). Yield 87%, off white solid, m.p. 199–201 °C (Lit. 198–200 °C); ³⁶ IR (KBr, ν cm⁻¹) 3402, 3393, 3279, 1666, 1620, 1504, 1435, 1234, 1134; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.27 (s, 1H), 10.86 (s, 1H), 8.85 (t, *J* = 5.3 Hz, 1H), 8.77 (s, 1H), 8.28–8.19 (m, 1H), 7.61 (d, *J* = 7.7 Hz, 1H), 7.54 (d, *J* = 6.0 Hz, 1H), 7.35 (d, *J* = 8.0 Hz, 1H), 7.30–7.23 (m, 2H), 7.21 (s, 1H), 7.07 (t, *J* = 7.4 Hz, 1H), 6.99 (t, *J* = 7.3 Hz, 1H), 3.54–3.49 (m, 2H), 2.95 (t, *J* = 7.3 Hz, 2H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 182.7, 163.9, 139.0, 136.7, 127.7, 126.7, 123.9, 123.2, 123.0, 121.8, 121.4, 118.8, 118.7, 113.0, 112.6, 112.1, 111.9, 39.9, 25.4; ESI(FAB) *m/z* calcd for C₂₀H₁₈N₃O₂: 332.14 (M + H)⁺, found 332.15 (M + H)⁺ and 354.12 (M + Na)⁺. *5*-(1*H*-Indol-3-yl)-1-(5-methoxy-1*H*-indol-3-yl)pentane-1,2-dione (**10b**). Yield 82%, pale yellow solid, m.p. 157–158 °C; IR (KBr, ν cm⁻¹): 3394, 3294, 3202, 1597, 1481, 1435, 1265, 1211, 1142, 802, 741, 447, 401; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.15 (s, 1H), 10.86 (s, 1H), 8.80 (t, *J* = 5.9 Hz, 1H), 8.71 (d, *J* = 3.3 Hz, 1H), 7.76 (d, *J* = 2.4 Hz, 1H), 7.61 (d, *J* = 7.8 Hz, 1H), 7.44 (d, *J* = 8.8 Hz, 1H), 7.35 (d, *J* = 8.0 Hz, 1H), 7.21 (d, *J* = 1.9 Hz, 1H), 7.10–7.06 (m, 1H), 6.99 (t, *J* = 7.2 Hz, 1H), 6.95–6.85 (m, 1H), 3.80 (s, 3H), 3.54–3.49 (m, 2H), 2.96 (t, *J* = 7.4 Hz, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 182.4, 164.0, 156.4, 139.0, 136.7, 131.5, 127.7, 123.1, 121.4, 118.8, 118.8, 113.8, 113.3, 112.5, 112.0, 111.9, 103.9, 55.8, 39.3, 25.3; ESI(FAB) *m/z* calcd for C₂₁H₁₉N₃O₃: 362.39 (M + H)⁺, found 362.15 (M + H)⁺ and 384.12 (M + Na)⁺. *N*-(2-(1*H*-Indol-3-yl)ethyl)-2-(5-bromo-1*H*-indol-3-yl)-2-

oxoacetamide (10c). Yield 84%, yellow solid, m.p. 198–200 °C; IR (KBr, ν cm⁻¹): 3418, 3256, 1605, 1504, 1435, 1366, 1227, 1219, 1134, 795, 748, 602, 463, 447, 401; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.44 (s, 1H), 10.86 (s, 1H), 8.89 (t, *J* = 6.0 Hz, 1H), 8.82 (d, *J* = 3.1 Hz, 1H), 8.36 (d, *J* = 1.8 Hz, 1H), 7.61 (d, *J* = 7.8 Hz, 1H), 7.52 (d, *J* = 8.6 Hz, 1H), 7.42 (dd, *J* = 8.6, 2.0 Hz, 1H), 7.35 (d, *J* = 8.1 Hz, 1H), 7.20 (d, *J* = 2.1 Hz, 1H), 7.07 (t, *J* = 7.0 Hz, 1H), 6.99 (t, *J* = 7.0 Hz, 1H), 3.54–3.49 (m, 2H), 2.95 (t, *J* = 7.5 Hz, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 182.6, 163.5, 140.1, 136.6, 135.5, 128.5, 127.6, 126.5, 123.8, 123.2, 121.4, 118.8, 115.8, 115.2, 112.3, 111.8, 39.3, 25.3; ESI(FAB) *m/z* calcd for C₂₀H₁₅BrN₃O₂: 408.10 (M-H)⁺, found 408.10 (M-H)⁺. *N*-(2-(1*H*-Indol-3-yl)ethyl)-2-(5-fluoro-1*H*-indol-3-yl)-2-oxoacetamide (**10d**). Yield 93%, cream colour solid, m.p. 241–242 °C; IR (KBr, ν cm⁻¹): 3410, 3356, 3279, 1659, 1620, 1504, 1435, 1234, 1180, 1134, 802, 741, 447, 401; ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.37 (s, 1H), 10.86 (s, 1H), 8.90 (t, *J* = 6.0 Hz, 1H), 8.84 (s, 1H), 7.92 (dd, *J* = 9.7, 2.6 Hz, 1H), 7.61 (d, *J* = 7.8 Hz, 1H), 7.56 (dd, *J* = 8.8, 4.6 Hz, 1H), 7.35 (d, *J* = 8.1 Hz, 1H), 7.21 (d, *J* = 2.2 Hz, 1H), 7.17–7.11 (m, 1H), 7.10–7.04 (m, 1H), 7.02–6.96 (m, 1H), 3.55–3.50 (m, 2H), 2.96 (t, *J* = 7.5 Hz, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 182.5, 163.6, 160.6, 158.3, 140.4, 136.7, 133.3, 127.7, 127.5, 127.4, 123.2, 121.4, 118.8, 118.7, 114.4, 114.3, 112.7, 112.6, 112.1, 112.0, 111.9, 106.8, 106.6, 39.3, 25.3; ESI(FAB) *m/z* calcd for C₂₀H₁₇FN₃O₂: 350.13 (M+H)⁺, found 350.12 (M+H)⁺.

16. Kirk KL. J. Fluorine Chem. 2006; 127:1013.

Figure 1.
Representative examples of bisindole alkaloids as antibacterial and anticancer agents

Figure 2.
Rational design of bis(indolyl)glyoxylamides **10a-n**

Figure 3.
Time dependent killing of *E.coli*, *P.putida*, *B. subtilis* and *S. aureus* upon treatment with 10d, 10g and 10i ($3 \times \text{MIC}$)

Figure 4.
Immunoblot analysis of cleaved PARP1 protein with **10a** and **10f** in PC-3 cells

Scheme 1.
Synthesis of bis(indolyl)glyoxylamides **10a-n**

Table 1

In-vitro antibacterial activity of bis(indolyl)glyoxylamides

Compd.	R ¹	R ²	R ³	ZOI (mm) and MIC (µg/mL) values											
				Gram-negative						Gram-positive					
				<i>E. coli</i>		<i>P. putida</i>		<i>K. pneumoniae</i>		<i>B. subtilis</i>		<i>S. aureus</i>			
				ZOI	MIC	ZOI	MIC	ZOI	MIC	ZOI	MIC	ZOI	MIC	ZOI	MIC
10a	H	H	H	15	50	14	50	14	100	15	50	15	50		
10b	OMe	H	H	15	100	15	100	15	50	-	-	-	-		
10c	Br	H	H	16	50	14	100	15	100	14	100	15	100		
10d	F	H	H	20	12.5	18	12.5	18	12.5	18	12.5	17	25		
10e	H	OMe	H	14	> 50	15	> 50	15	100	15	> 100	14	100		
10f	H	F	H	15	100	14	> 100	14	> 50	-	-	-	-		
10g	H	H	CH ₃	18	12.5	17	> 25	17	25	18	> 25	16	50		
10h	H	H	CH ₂ CH ₃	14	> 50	12	> 100	13	> 100	14	100	14	100		
10i	H	H	4-ClC ₆ H ₄ CH ₂	18	12.5	18	12.5	18	> 12.5	17	> 25	17	> 25		
10j	Br	H	4-ClC ₆ H ₄ CH ₂	15	100	14	> 100	14	> 50	14	100	13	100		
10k	MeO	H	4-ClC ₆ H ₄ CH ₂	13	> 100	15	50	-	-	-	-	-	-		
10l	F	H	4-ClC ₆ H ₄ CH ₂	14	100	14	100	12	> 100	13	> 50	13	100		
10m	H	MeO	4-ClC ₆ H ₄ CH ₂	15	50	16	50	15	> 50	-	-	-	-		
10n	H	H	4-FC ₆ H ₄ CH ₂	15	100	15	100	13	> 100	12	> 100	14	> 100		
Chloramphenicol				22	16	21	16	20	16	22	16	21	16		

^aThe zone of inhibition and MIC values for compounds with significant activity are shown in bold

Table 2

in vitro anticancer activity of bis(indolyl)glyoxylamides

IC ₅₀ (μM)										
Compd.	R ¹	R ²	R ³	HEK 293T	C4-2	HeLa	PC-3	MDA-MB-231	BxPC-3	
10a	H	H	H	97.72	71.51	48.85	38.45	48.7	63.95	
10b	OMe	H	H	> 100	> 100	> 100	> 100	> 100	> 100	
10c	Br	H	H	> 100	> 100	> 100	> 100	> 100	> 100	
10d	F	H	H	> 100	> 100	> 100	> 100	> 100	> 100	
10e	H	OMe	H	> 100	> 100	> 100	> 100	> 100	> 100	
10f	H	F	H	69.82	46.03	22.34	24.05	21.13	29.94	
10g	H	H	CH ₃	> 100	> 100	> 100	> 100	> 100	> 100	
10h	H	H	CH ₂ CH ₃	> 100	> 100	> 100	> 100	> 100	> 100	
10i	H	H	4-ClC ₆ H ₄ CH ₂	> 100	> 100	> 100	> 100	> 100	> 100	
10j	Br	H	4-ClC ₆ H ₄ CH ₂	> 100	> 100	> 100	> 100	> 100	> 100	
10k	MeO	H	4-ClC ₆ H ₄ CH ₂	> 100	> 100	> 100	> 100	> 100	> 100	
10l	F	H	4-ClC ₆ H ₄ CH ₂	> 100	> 100	> 100	> 100	> 100	> 100	
10m	H	MeO	4-ClC ₆ H ₄ CH ₂	> 100	> 100	> 100	> 100	> 100	> 100	
10n	H	H	4-FC ₆ H ₄ CH ₂	> 100	> 100	> 100	> 100	> 100	> 100	
Doxorubicin				3.1	1.85	5	9.5	6.75	13	

IC₅₀ values are the mean of three different experiments performed in duplicate